NCT00772304View on ClinicalTrials.gov

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2008

Conditions
Allergic Rhinitis
Interventions
DRUG

Olopatadine 0.6% / Azelastine 137 mcg

single dose; 2 sprays per nostril

Trial Locations (1)

76134

Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY